CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 29 enrolled
Drug / intervention
clofarabinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00416351
NCT00416351Phase 2Completed
CompareCT.gov

A Phase I/II Study of Clofarabine in Patients With Relapsed T-Cell and NK-Cell Lymphomas

Memorial Sloan Kettering Cancer Center·interventional·Posted Dec 28, 2006·Updated May 17, 2022

In Brief

A Phase 2 clinical trial evaluating clofarabine for Leukemia and 2 related conditions. Completed, enrolled 29 participants across 3 sites.

Detailed Summary

RATIONALE: Drugs used in chemotherapy, such as clofarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase I/II trial is studying the side effects and best dose of clofarabine and to see how well it works in treating patients with T-cell or natural killer-cell lymphoma that has relapsed or not responded to previous treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukemia, Lymphoma, Small Intestine Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI), University of Rochester, The Cleveland Clinic

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 28, 2006
Enrollment StartJun 27, 2006
Primary CompletionMar 1, 2021
TodayJul 2, 2026
Enrollment to primary: 14.7 yearsPosted 19.5 years ago

Interventions

clofarabinedrug